Patents by Inventor Jonathan Leighton

Jonathan Leighton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-MICROBIAL ANTIBODY SIGNATURES OF INFLAMMATORY BOWEL DISEASE AND USES THEREOF
    Publication number: 20240053336
    Abstract: The present invention relates anti-microbial antibody signatures of inflammatory bowel disease and their use in early and accurate diagnosis of disease including ulcerative colitis (UC) and Crohn's disease (CD).
    Type: Application
    Filed: August 11, 2023
    Publication date: February 15, 2024
    Inventors: Mahasish SHOME, Lusheng SONG, Yunro CHUNG, Jonathan LEIGHTON, Joshua LABAER, Ji QIU
  • Methods for detecting novel autoantibodies in Crohn's disease
    Patent number: 10648978
    Abstract: Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 12, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Arizona Board of Regents on behalf of Arizona State University
    Inventors: Haoyu Wang, Ji Qiu, Joshua LaBaer, Jonathan Leighton, Shabana Pasha
  • METHODS FOR DETECTING NOVEL AUTOANTIBODIES IN CROHN'S DISEASE
    Publication number: 20180224448
    Abstract: Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 9, 2018
    Inventors: Haoyu Wang, Ji Qiu, Joshua LaBaer, Jonathan Leighton, Shabana Pasha